secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forbion European Acquisition Corp. (—)
CIK:        0001874495
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268401
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forbion European Acquisition Corp. completes business combination with enGene; combined entity trades as ENGN
--------------------------------------------------------------------------------

- Business combination closed Oct 31, 2023; enGene becomes subsidiary of new public company enGene Holdings Inc.
- Gross proceeds of ~$138M from trust ($25M) and PIPE ($113M); 10.4M FEAC shares redeemed.
- Lead therapy EG-70 (detalimogene voraplasmid) in pivotal Phase 2 for BCG-unresponsive NMIBC; interim results expected mid-2024.
- enGene management led by CEO Jason Hanson continues at helm; prior FEAC directors and officers resigned.
- New enGene ordinary shares and warrants trade on Nasdaq under ENGN and ENGNW as of Nov 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/d538206d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer